Hope For Healing: Glioblastoma Treatments, Costs & Waiting Periods Compared

If you've ever wondered why so many British families turn to crowdfunding campaigns when cancer strikes, the story of glioblastoma—the most common form of malignant brain tumour in adults—offers a revealing case study. Each year, about 3,200 to 4,500 people in the UK receive this diagnosis. For most, the NHS provides surgery, radiotherapy, and chemotherapy as part of a standard protocol. Yet survival rates remain grim: the median is 12–15 months, and fewer than 5% live beyond five years.

That's where the system begins to fall apart. The best experimental therapies—from immunotherapy to wearable electrical field devices—remain outside NHS coverage, priced at levels that can quickly exceed household incomes. For families like Asta Pratapaviciene and her partner Raimondas, who recently launched a GoFundMe appeal, the gap between NHS provision and promising private options is wide enough to force difficult, public pleas for help.

The Standard Path: What the NHS Provides

The NHS follows what's called the Stupp protocol, a combination of:

• Surgery: removing as much tumour as possible. Average waiting time: 2–3 weeks from diagnosis.
• Radiotherapy: typically 60 Gy in 30 sessions over six weeks.
• Temozolomide chemotherapy: taken alongside radiotherapy and continued in cycles.

For patients who can undergo all three, survival can stretch to 16–18 months—a meaningful but still short reprieve. The treatment is covered entirely by the NHS. In private hospitals, however, surgery alone can cost £20,000–40,000, with radiotherapy adding another £12,000–20,000.

But the shortcoming isn't just survival odds—it's also time. Many NHS oncology wards face shortages that delay radiotherapy by several weeks beyond guideline targets. Those delays matter because glioblastomas grow fast.

Beyond the Basics: Private and Experimental Therapies

When NHS care hits its ceiling, patients look elsewhere. Here's what they find:

Tumour Treating Fields (Optune)

• Wearable cap using low‑intensity electric fields.
• Evidence: prolongs survival by ~5 months.
• Cost: £17,000–20,000 per month.
• Coverage: not approved by NICE, so NHS won't pay.

Bevacizumab (Avastin)

• Anti‑angiogenic drug that limits tumour blood supply.
• Cost: £6,000–8,000 per infusion (often every two weeks).
• Evidence: may slow tumour growth, but has a limited effect on overall survival.
• NHS status: not funded for brain tumours.

Immunotherapies (CAR‑T, checkpoint inhibitors)

• Mostly offered abroad or through rare UK trials.
• Cost: £200,000+ privately.
• Evidence: mixed, but some long‑term responders documented.
• Waiting time: months to years, depending on trial eligibility.

Vaccine‑based treatments (e.g., DCVax‑L)

• Experimental, using a patient's own dendritic cells.
• Cost: £150,000–250,000, not available on NHS.

For most patients, crowdfunding is the only way to reach these treatments, which is why appeals like "You're My Only Hope" keep surfacing across social media.

The Human Cost of Delays

Delays have consequences, both clinical and emotional. Data from Cancer Research UK confirms that 21% of GBM patients receive no active treatment—sometimes because they're too ill, but often because waiting times push them past the therapeutic window. Families describe the experience as a race against both the tumour and the system.

What Patients and Families Need to Know

So what should families facing a glioblastoma diagnosis consider when weighing treatment options?

• Start with NHS care quickly: Surgery, radiotherapy, and chemotherapy remain the most accessible first steps. Advocate for fast referrals—you're entitled to be seen by a consultant within two weeks.
• Ask about trial eligibility early: NIHR and Cancer Research UK list active trials. Slots fill fast, and many have stringent genetic or health criteria.
• Understand private cost commitments: Optune or bevacizumab can add six figures annually. Few families can sustain this without outside help.
• Weigh benefit vs burden: Extending progression‑free survival by months comes with side effects, quality‑of‑life questions, and enormous financial strain.

Will Treatment Reach Patients?

Glioblastoma is a crushing disease that reveals chinks in healthcare protocols: new treatments and groundbreaking science exist, but real access is rare and expensive.

For now, families like Asta and Raimondas are left to ask strangers online for help bridging the gap. The choices, then, aren't just medical. They're financial, ethical, and profoundly human.